简介:
- 作者: Honghan Chen, Ning Huang, Weitong Xu, Yu Yang, Fangfang Wang, Hui Gong, Jiao Zhou, Haoran Tai, Tingting Zhao, Jian Zhang, Ying Li, Ge Liang, Minghai Tang, Jie Li, Ming Yang, Jin Liu, Xiaoli Huang, Hengyi Xiao
- 杂志: Signal Transduction and Targeted Therapy
- Doi: https://www.doi.org/10.1038/s41392-026-02576-w
- 出版日期: 2026/2/19
摘要
The catabolism of glutamine is essential for living organisms, so that its first step, driven by glutaminase 1 (GLS1), generally referred to as glutaminolysis, plays important roles in physiological metabolism. However, the status and impact of glutaminolysis in pathological contexts such as aging and age-related diseases remain elusive. In this study, through metabolomics analysis and different aging models, we verified the hyperactivation status of glutaminolysis in senescent cells and aged Drosophila and mice, which we term “hyperglutaminolysis”. We further confirmed the aging-promoting role of this hyperglutaminolysis by addition and removal intervention experiments. Intriguingly, a novel signaling axis connecting to senescence-associated persistent mTORC1 activation was found. This pathway begins with glutaminase-catalyzed production of ammonium and glutamate, which drives arginine biosynthesis and is subsequently sensed by CASTOR1, leading to persistent mTORC1 activation. The regulatory roles of two key enzymes within this cascade, GLS1 and argininosuccinate lyase (ASL), were specifically investigated and verified by cellular and in vivo experiments, including those using stress-promoted and naturally aged animals, combined with GLS1 and ASL knockdown, and multiple rounds of metabolite analysis. In conclusion, our work positions dysregulated glutaminolysis as a key driver of aging and delineates a previously unrecognized molecular cascade that directly links glutaminolysis, arginine biosynthesis, and mTORC1 activation. These findings significantly expand our understanding of the relationship between glutamine catabolism and aging and are valuable for identifying novel intervention targets aimed at mitigating aging-related processes.
关于派真
作为一家专注于AAV 技术十余年,深耕基因治疗领域的CRO&CDMO,派真生物可提供从载体设计、构建到 AAV、慢病毒和 mRNA 服务的一站式解决方案。凭借深厚的技术实力、卓越的运营管理和高标准的服务交付,我们为全球客户提供一站式CMC解决方案,包括从早期概念验证、成药性评估到IIT、IND及BLA的各个阶段。
凭借我们独立知识产权的π-alphaTM 293 细胞AAV高产技术平台,我们能将AAV产量提高多至10倍,每批次产量可达1×10¹⁷vg,以满足多样化的商业化和临床项目需求。此外,我们定制化的mRNA和脂质纳米颗粒(LNP)产品及服务覆盖药物和疫苗开发的各个阶段,从研发到符合GMP的生产,提供端到端的一站式解决方案。